Raysearch Laboratories AB (publ) Interim Report January 1–June 30, 2015

HALF-YEAR (JANUARY–JUNE, 2015)

• Net sales for the period amounted to SEK 165.1 M (105.8), of which RayStation® accounted for SEK 106.6 M (50.9)
• Profit after tax totaled SEK 22.4 M (5.9) and earnings per share were SEK 0.65 (0.17)
• Operating profit amounted to SEK 31.0 M (8.4)
• Cash flow was a negative SEK 2.3 M (neg: 11.3)
• Order intake excluding service agreements amounted to SEK 158.3 M (101.6), of which RayStation® accounted for SEK 124.4 M (59.1)

SECOND QUARTER (APRIL–JUNE, 2015)

• Net sales for the period amounted to SEK 77.3 M (51.9), of which RayStation® accounted for SEK 53.9 M (23.6)
• Loss after tax totaled SEK 2.6 M (profit: 1.0) and loss per share was SEK 0.08 (earnings: 0.00)
• Operating loss amounted to SEK 2.1 M (profit: 2.1)
• Cash flow was a negative SEK 10.1 M (neg: 7.9)
• Order intake excluding service agreements amounted to SEK 72.0 M (46.8), of which RayStation® accounted for SEK 55.3 M (24.4)
• RayStation® order backlog totaled SEK 33.8 M (66.5)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

• The first proton therapy treatments with RayStation® for Mevion S250 in the US
• Texas Center for Proton Therapy, part of the national collaboration The US Oncology Network, has selected RayStation®
• Peter Thysell was appointed new CFO, Björn Hårdemark Deputy CEO, Kjell Eriksson new Chief Science Officer and Victoria Sörving new General Counsel, and all join executive management

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• RaySearch has secured a number of major orders from some of the world’s largest and most respected cancer clinics, including the University of Texas MD Anderson Cancer Center and the University of Florida Health Proton Therapy Institute in the US, as well as Gustave Roussy in France
• Long-term collaboration agreement signed with Accuray regarding the RayCare® Oncology Information System

"Our success with RayStation® continues and the strong start to the year remains unabated. During the first half of the year, revenues from RayStation® rose approximately 129 percent to SEK 116.6 M (50.9). Overall, revenues rose 56.0 percent to SEK 165.1 M (105.8) and operating profit increased to SEK 31.0 M (8.4), representing the highest-ever sales and earnings for the first half-year,” says Johan Löf, CEO of RaySearch.

"In the third quarter, we have already secured several key orders from some of the world’s largest and most respected cancer clinics, including MD Anderson and the University of Florida Health Proton Therapy Institute in the US, and Gustave Roussy in France. We secured these orders in direct competition with our main competitors, which I consider firm confirmation that our system offers major benefits,” says Johan Löf .

The information in the interim report is such that RaySearch is required to disclose publicly in accordance with the Swedish Securities and Clearing Operations Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on August 28, 2015 at 7:45 a.m.

About Us

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150827006116/en/